Colgate-Palmolive (NYSE:CL) Price Target Raised to $105.00 at Stifel Nicolaus

Colgate-Palmolive (NYSE:CL) had its target price raised by Stifel Nicolaus from $95.00 to $105.00 in a research report released on Monday, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on the company. Evercore ISI lifted their price objective on Colgate-Palmolive from $100.00 to $106.00 and gave the company an outperform rating in a research note on Thursday, July 18th. Morgan Stanley lifted their target price on Colgate-Palmolive from $101.00 to $103.00 and gave the company an overweight rating in a research report on Tuesday, May 28th. Citigroup boosted their price target on shares of Colgate-Palmolive from $103.00 to $112.00 and gave the stock a buy rating in a research note on Wednesday, July 10th. Bank of America raised their price objective on shares of Colgate-Palmolive from $100.00 to $110.00 and gave the company a buy rating in a research note on Wednesday, July 10th. Finally, Barclays upped their target price on shares of Colgate-Palmolive from $85.00 to $91.00 and gave the stock an equal weight rating in a research note on Friday, July 19th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $98.58.

Colgate-Palmolive Trading Down 0.1 %

Shares of CL stock opened at $96.49 on Monday. The company has a 50-day moving average of $95.72 and a two-hundred day moving average of $89.93. The firm has a market cap of $79.16 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 3.49 and a beta of 0.39. Colgate-Palmolive has a 1-year low of $67.62 and a 1-year high of $99.63. The company has a debt-to-equity ratio of 13.21, a current ratio of 1.06 and a quick ratio of 0.70.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, April 26th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.96 billion. Colgate-Palmolive had a net margin of 13.22% and a return on equity of 485.40%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $0.73 EPS. On average, analysts predict that Colgate-Palmolive will post 3.53 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Friday, July 19th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 2.07%. The ex-dividend date of this dividend is Friday, July 19th. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 63.29%.

Insider Buying and Selling

In other Colgate-Palmolive news, insider Sally Massey sold 12,226 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $94.06, for a total transaction of $1,149,977.56. Following the sale, the insider now owns 13,924 shares of the company’s stock, valued at $1,309,691.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Colgate-Palmolive news, insider Sally Massey sold 12,226 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $94.06, for a total value of $1,149,977.56. Following the completion of the transaction, the insider now owns 13,924 shares in the company, valued at $1,309,691.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John W. Kooyman sold 3,497 shares of Colgate-Palmolive stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $93.47, for a total value of $326,864.59. Following the sale, the insider now owns 3,181 shares in the company, valued at approximately $297,328.07. The disclosure for this sale can be found here. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Colgate-Palmolive

Several large investors have recently modified their holdings of CL. Norges Bank acquired a new stake in Colgate-Palmolive during the 4th quarter worth $731,843,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Colgate-Palmolive by 27.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 41,067,130 shares of the company’s stock worth $3,698,096,000 after buying an additional 8,933,912 shares during the last quarter. Swedbank AB acquired a new position in Colgate-Palmolive in the 1st quarter valued at about $286,370,000. Magellan Asset Management Ltd raised its stake in Colgate-Palmolive by 4,162.6% during the 4th quarter. Magellan Asset Management Ltd now owns 2,016,290 shares of the company’s stock valued at $160,718,000 after acquiring an additional 1,968,988 shares during the last quarter. Finally, Confluence Investment Management LLC acquired a new stake in Colgate-Palmolive during the 1st quarter worth approximately $130,622,000. 80.41% of the stock is owned by institutional investors and hedge funds.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.